Christopher V. DeSimone, MD, PhD, and Stephen L. Kopecky, MD, discuss lipid management and the use of inclisiran, an siRNA drug that inhibits the RNA from making PCSK9. www.medscape.com/viewarticle/...
The question that needs to be asked is how many patients have who taken this injectable pcsk9i reduced their cholesterol and have also reduced their risk of heart attacks?
I wonder if the patients that stop their self injection pcsk9i are doing so because of side effects or they get tired of the injections. Would love to get patient perspectives rather than just those of medical personnel.
My doctor mentioned that many of his patients just didn’t like injecting themselves, so they eventually opted for the infusion shots. I’m just concerned about the side effects.
